HRTX
Heron Therapeutics, Inc.
There isn't enough reported data to score HRTX yet.
HRTX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Strong |
HRTX's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
HRTX PE Valuation
HRTX has no meaningful PE right now: it lost money over the past year.
HRTX Forward outlook
There aren't enough analyst estimates for HRTX to show an outlook.
HRTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.11 | -$0.02 |
| Q2 2026 | -$0.18 | -$0.16 |
| Q1 2026 | -$0.17 | -$0.11 |
| Q4 2025 | -$0.12 | -$0.03 |
| Q3 2025 | -$0.09 | +$0.09 |
| Q2 2025 | -$0.02 | +$0.30 |
| Q1 2025 | -$0.06 | +$0.55 |
| Q4 2024 | -$0.09 | +$0.77 |
HRTX is still losing money, but far less than before: $0.11 per share over the past year, against $2.52 at its worst in mid-2021.
HRTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $35.3M | -7.8% |
| Q2 2026 | $37.7M | +1.3% |
| Q1 2026 | $34.7M | -11% |
| Q4 2025 | $40.6M | -0.5% |
| Q3 2025 | $38.2M | +16% |
| Q2 2025 | $37.2M | +3.3% |
| Q1 2025 | $38.9M | +12% |
| Q4 2024 | $40.8M | +19% |
HRTX's revenue is shrinking: $35M last quarter, down 7.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -4.7% | +6 points |
| Q2 2026 | -5.4% | -1 points |
| Q1 2026 | -14% | -22 points |
| Q4 2025 | 0.1% | -10 points |
| Q3 2025 | -11% | +2.9 points |
| Q2 2025 | -4.4% | +14 points |
| Q1 2025 | 8.1% | +22 points |
| Q4 2024 | 10% | +40 points |
HRTX's operating margin was −4.7% last quarter, up 6 points from the same quarter a year ago.
HRTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$896K | -167% |
| Q2 2026 | -$2.4M | +$8.7M |
| Q1 2026 | -$1.9M | +$7M |
| Q4 2025 | -$9.2M | +$3.2M |
| Q3 2025 | $1.3M | -55% |
| Q4 2024 | -$12.4M | -663% |
| Q3 2024 | $2.9M | +$12.9M |
| Q4 2023 | $2.2M | +$40.2M |
HRTX has burned cash in almost every quarter: −$14M over the past year, against −$31M the year before.
HRTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +584K shares |
| 1 year | +12% | +20.6M shares |
| 3 years | +32% | +45.9M shares |
| 5 years | +94% | +92.5M shares |
| Available history | +133% | +109M shares |
HRTX has 191M diluted shares, up 12% from a year ago.
HRTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -2.8x | Net Cash |
| Q2 2025 | 37.5x | High |
HRTX has more cash than debt.
HRTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 18.9 | Oversold |
HRTX's weekly RSI is 38 (neutral) and its Stochastic is 19 (oversold).
HRTX PE vs Healthcare Sector
HRTX has no meaningful PE right now: it lost money over the past year.
HRTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.33 | 0% above |
| 20 week MA | $0.37 | 11% below |
| 50 week MA | $0.76 | 57% below |
| 100 week MA | $1.24 | 73% below |
| 200 week MA | $1.64 | 80% below |
HRTX is in a downtrend: it's below all five of its weekly moving averages, and 80% below its 200-week average.
HRTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $24.1 | $20.7 | -14% |
| 2021 | $20.7 | $10.2 | -51% |
| 2022 | $10.2 | $2.57 | -75% |
| 2023 | $2.57 | $1.70 | -34% |
| 2024 | $1.70 | $1.55 | -8.8% |
| 2025 | $1.55 | $1.28 | -17% |
| 2026 YTD | $1.28 | $0.33 | -74% |
HRTX has finished every year since 2020 lower, and it's down 74% so far in 2026.